JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Endocrinology Research Centre of Health Care Ministry of Russian Federation, Dmitriya Ulyanova, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465364.6", 
          "name": [
            "Endocrinology Research Centre of Health Care Ministry of Russian Federation, Dmitriya Ulyanova, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Galstyan", 
        "givenName": "Gagik R.", 
        "id": "sg:person.014547532627.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014547532627.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel", 
          "id": "http://www.grid.ac/institutes/grid.12136.37", 
          "name": [
            "Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tirosh", 
        "givenName": "Amir", 
        "id": "sg:person.01363242403.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363242403.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayan-Cauca, Colombia", 
          "id": "http://www.grid.ac/institutes/grid.412186.8", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayan-Cauca, Colombia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vargas-Uricoechea", 
        "givenName": "Hernando", 
        "id": "sg:person.0666260352.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666260352.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Singapore, Singapore", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Sanofi, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mabunay", 
        "givenName": "Maria Aileen", 
        "id": "sg:person.014000313025.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014000313025.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coudert", 
        "givenName": "Mathieu", 
        "id": "sg:person.016236166301.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016236166301.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Mumbai, India", 
          "id": "http://www.grid.ac/institutes/grid.497468.0", 
          "name": [
            "Sanofi, Mumbai, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naqvi", 
        "givenName": "Mubarak", 
        "id": "sg:person.011123407075.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011123407075.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pilorget", 
        "givenName": "Valerie", 
        "id": "sg:person.0625112120.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625112120.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Imperial College London Diabetes Centre, Al Ain, United Arab Emirates", 
          "id": "http://www.grid.ac/institutes/grid.488461.7", 
          "name": [
            "Imperial College London Diabetes Centre, Al Ain, United Arab Emirates"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khan", 
        "givenName": "Niaz", 
        "id": "sg:person.012512701733.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012512701733.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11892-018-1002-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103472007", 
          "https://doi.org/10.1007/s11892-018-1002-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40618-014-0069-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004817237", 
          "https://doi.org/10.1007/s40618-014-0069-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-0568-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112140157", 
          "https://doi.org/10.1007/s13300-019-0568-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-09", 
    "datePublishedReg": "2022-05-09", 
    "description": "IntroductionThe clinical benefits of insulin glargine 300\u00a0U/mL (Gla-300) have been confirmed in randomised clinical trials (EDITION programme and BRIGHT) and real-world studies in the USA and Western Europe. ATOS evaluated the real-world effectiveness and safety of Gla-300 in wider geographic regions (Asia, the Middle East, North Africa, Latin America and Eastern Europe).MethodsThis prospective observational, international study enrolled adults (\u2265\u200918\u00a0years) with type 2 diabetes mellitus (T2DM) uncontrolled [haemoglobin A1c (HbA1c)\u2009>\u20097% to\u2009\u2264\u200911%] on\u2009one or more oral anti-hyperglycaemic drugs (OADs) who had been advised by their treating physician to add Gla-300 to their existing treatment. The primary endpoint was achievement of a pre-defined individualised HbA1c target at month 6.ResultsOf the 4550 participants included, 4422 (51.8% female) were eligible for assessment. The mean\u2009\u00b1\u2009standard deviation (SD) age was 57.2\u2009\u00b1\u200910.8\u00a0years, duration of diabetes was 10.2\u2009\u00b1\u20096.2\u00a0years and baseline HbA1c was 9.28\u2009\u00b1\u20091.0%. The proportion of participants reaching their individualised glycaemic target was 25.2% [95% confidence interval (CI) 23.8\u201326.6%] at month 6 and 44.5% (95% CI 42.9\u201346.1%) at month 12. At months 6 and 12, reductions were observed in HbA1c (\u22121.50% and\u2009\u22121.87%) and fasting plasma glucose (\u22123.42 and\u2009\u22123.94\u00a0mmol/L). Hypoglycaemia incidence was low, and body weight change was minimal. Adverse events were reported in 283 (6.4%) participants, with 57 (1.3%) experiencing serious adverse events.ConclusionIn a real-world setting, initiation of Gla-300 in people with T2DM uncontrolled on OADs resulted in improved glycaemic control and low rates of hypoglycaemia with minimal weight change.Trial RegistrationClinicaltrials.gov number NCT03703869.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01266-4", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "oral anti-hyperglycaemic drugs", 
      "Gla-300", 
      "month 6", 
      "adverse events", 
      "insulin glargine 300 U/mL", 
      "glargine 300 U/mL", 
      "type 2 diabetes mellitus", 
      "duration of diabetes", 
      "insulin-na\u00efve people", 
      "weight change", 
      "serious adverse events", 
      "insulin glargine 300", 
      "improved glycaemic control", 
      "standard deviation age", 
      "real-world effectiveness", 
      "proportion of participants", 
      "anti-hyperglycaemic drugs", 
      "real-world study", 
      "body weight changes", 
      "minimal weight change", 
      "glycaemic targets", 
      "primary endpoint", 
      "baseline HbA1c", 
      "glargine 300", 
      "hypoglycaemia incidence", 
      "glycaemic control", 
      "diabetes mellitus", 
      "deviation age", 
      "month 12", 
      "clinical benefit", 
      "World Effectiveness", 
      "plasma glucose", 
      "clinical trials", 
      "type 2", 
      "real-world setting", 
      "HbA1c", 
      "lower rates", 
      "international studies", 
      "participants", 
      "safety", 
      "MethodsThis", 
      "mellitus", 
      "T2DM", 
      "hypoglycaemia", 
      "geographic regions", 
      "diabetes", 
      "ConclusionIn", 
      "years", 
      "incidence", 
      "physicians", 
      "trials", 
      "endpoint", 
      "study", 
      "drugs", 
      "adults", 
      "target", 
      "age", 
      "treatment", 
      "duration", 
      "glucose", 
      "events", 
      "people", 
      "mL", 
      "changes", 
      "initiation", 
      "proportion", 
      "setting", 
      "assessment", 
      "control", 
      "effectiveness", 
      "benefits", 
      "rate", 
      "reduction", 
      "ATOS", 
      "wide geographic regions", 
      "USA", 
      "region", 
      "Western Europe", 
      "Europe", 
      "achievement"
    ], 
    "name": "Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Na\u00efve People with Type 2 Diabetes: the ATOS Study", 
    "pagination": "1187-1202", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147731740"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01266-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35532858"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01266-4", 
      "https://app.dimensions.ai/details/publication/pub.1147731740"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_942.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01266-4"
  }
]

Download the RDF metadata as:  json-ld nt turtle xml License info

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      21 PREDICATES      109 URIs      97 LITERALS      7 BLANK NODES